Table 2 Treatment-related adverse events
All patients ( N = 197) | ||
|---|---|---|
Any grade | Grade ≥3 | |
Any | 116 (58.9) | 23 (11.7) |
Proteinuria | 27 (13.7) | 0 |
Hot flush | 22 (11.2) | 0 |
White blood cell count decreased | 19 (9.6) | 3 (1.5) |
Neutrophil count decreased | 14 (7.1) | 2 (1.0) |
Asthenia | 13 (6.6) | 0 |
Occult blood positive | 12 (6.1) | 0 |
Aspartate aminotransferase increased | 12 (6.1) | 0 |
Bilirubin conjugated increased | 11 (5.6) | 0 |
Platelet count decreased | 10 (5.1) | 0 |
Alanine aminotransferase increased | 9 (4.6) | 1 (0.5) |
Blood thyroid stimulating hormone increased | 8 (4.1) | 0 |
Hypertriglyceridemia | 7 (3.6) | 1 (0.5) |
Decreased appetite | 7 (3.6) | 1 (0.5) |
Hypertension | 7 (3.6) | 2 (1.0) |
Gynecomastia | 7 (3.6) | 1 (0.5) |
Anemia | 7 (3.6) | 1 (0.5) |